Vaginal administration of allopregnanolone to postmenopausal women undergoing estrogen replacement therapy: Preliminary results

Maturitas

Volumn 46, Issue 2, 2003, Pages 147-152

  Navarro, Paula Andrea De A S ^a   Kaddouz, Delphine ^b   De Ziegler, Dominique ^b   Silva De Sá, Marcos Felipe ^a,b   Ferriani, Rui Alberto ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Columbia Research Laboratories ^*  (France)

Author keywords

Allopregnanolone; Endometrium; Hormonal replacement therapy; Menopause; Tolerability

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; AGENTS USED INTRAVAGINALLY; ELTANOLONE; ESTRADIOL VALERATE;

ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG TOLERABILITY; ENDOMETRIUM BIOPSY; ESTROGEN THERAPY; FEMALE; GEL; HEADACHE; HISTOPATHOLOGY; HUMAN; IATROGENIC DISEASE; INTRAVAGINAL DRUG ADMINISTRATION; LOW BACK PAIN; MASTALGIA; MENOPAUSAL SYNDROME; MENSTRUAL CYCLE; OUTCOMES RESEARCH; PATIENT COMPLIANCE; POSTMENOPAUSE; PRESCRIPTION; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; URINE RETENTION; UTERUS BLEEDING; VAGINA BLEEDING; VULVA PRURITUS;

EID: 0141957322     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(03)00188-9     Document Type: Article

References (33)

1. Whitehead M.I. The effects of oestrogens and progestagens on the postmenopausal endometrium. Maturitas. 1:1978;87-98.
2. Voigt L.F., Weiss N.S., Chu J., Daling J.R., McKnight B., van Belle G. Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet. 338:1991;274-277.
3. Hahn R.G. Compliance considerations with estrogen replacement: withdrawal bleeding and other factors. Am. J. Obstet. Gynecol. 161:1989;1854-1858.
4. Whitehead M.I., Hillard T.C., Crook D. The role and use of progestogens. Obstet. Gynecol. 75:1990;59S-76S.
5. Marsh M.S., Whitehead M.I. The practicalities of hormone replacement. Baillieres Clin. Endocrinol. Metab. 7:1993;183-202.
6. Nachtingall L.E. Enhancing patient compliance with hormone replacement therapy at menopause. Obstet. Gynecol. 75:1990;77S-80S.
7. Wren B.G., Brown L. Compliance with hormonal replacement therapy. Maturitas. 13:1991;17-21.
8. De Ziegler D., Bessis R., Frydman R. Vascular resistance of uterine arteries: physiological effects of estradiol and progesterone. Fertil. Steril. 55:1991;775-779.
9. Bulletti C., De Ziegler D., Flamigni C., Giacomucci E., Polli V., Boletti G., Franceschetti F. Targeted drug delivery in gynecology: the first uterine pass effect. Hum. Reprod. 12:1997;1073-1079.
10. Holzbauer M., Birmingham M.K., De Nicola A.F., Oliver J.T. In vivo secretion of 3α-hydroxy-5α-pregnan-20-one, a potent anesthetic steroid by the adrenal gland of the rat. J. Steroid Biochem. 22:1985;97-102.
11. Jung-Testas I., Hu Z.Y., Baulieu E.E., Robel P. Neurosteroids: biosynthesis of pregnanolone and progesterone in primary cultures of rat glial cells. Endocrinology. 125:1989;2083-2091.
12. Baulieu E.E., Robel P. Neurosteroids: a new brain function. J. Steroid Biochem. Mol. Biol. 37:1990;395-403.
13. Paul S.M., Purdy R.H. Neuroactive Steroids. FASEB J. 6:1992;2311-2322.
14. Akwa Y., Morfin R.F., Robel P., Baulieu E.E. Neurosteroid metabolism. Biochem. J. 288:1992;959-964.
15. Mellon S.H., Deschepper C.F. Neurosteroid biosynthesis: genes for adrenal steroidogenic enzymes are expressed in the brain. Brain Res. 629:1993;283-292.
16. Robel P., Baulieu E.E. Neurosteroids: biosynthesis and function. Trends Endocrinol. Metab. 5:1994;1-8.
17. Schmidt P.J., Purdy R.H., Moore P.H., Paul S.M., Rubinow D.R. Circulating levels of anxiolytic steroids in the luteal phase in women with premenstrual syndrome and in control subjects. J. Clin. Endocrinol. Metab. 79:1994;1256-1260.
18. Wang M., Seippel L., Purdy R.H. Relationship between symptom severity and steroid variation in women with premenstrual syndrome: study on serum pregnenolone sulfate, 5α-pregnan-3,20-dione and 3α-hydroxy-5α -pregnan-20-one. J. Clin. Endocrinol. Metab. 81:1996;1076-1082.
19. Bicíková M., Lapcík O., Hampl R., Starka L., Knuppen R., Haupt O., Dibbelt L. A novel radioimmunoassay of allopregnanolone. Steroids. 60:1995;210-213.
20. Genazzani A.R., Petraglia F., Bernardi F., Casarosa E., Salvestroni C., Tonetti A., Nappi R.E., Luisi S., Palumbo M., Purdy R.H., Luisi M. Circulating levels of allopregnanolone in humans: gender, age and endocrine influences. J. Clin. Endocrinol. Metab. 83:1998;2099-2103.
21. McEwen B.S. Non-genomic and genomic effects of steroids on neural activity. Trends Pharmacol. 12:1991;141-147.
22. Majewaska M.D. Neurosteroids: endogenous bimodal modulators of the GABA-A receptor. Mechanism of action and physiological significance. Prog. Neurobiol. 38:1992;379-395.
23. Baulieu E.E., Schumacher M., Koenig H., Jung-Testas I., Akwa Y. Progesterone as a neurosteroid: actions within the nervous system. Cell. Mol. Neurobiol. 16:1996;143-154.
24. Lane G., Siddle N.C., Ryder T.A., Pryse-Davies J., King R.J., Whitehead M.I. Dose dependent effects of oral progesterone on the oestrogenised postmenopausal endometrium. Br. Med. J. 287:1983;1241-1245.
25. Moyer D.L., Lignieres B., Driguez P., Pez J.P. Prevention of endometrial hyperplasia by progesterone during long-term estradiol replacement: influence of bleeding pattern and secretory changes. Fertil. Steril. 59:1993;992-997.
26. Wolf J.P., Hsiu J.G., Anderson T.L., Ulmann A., Baulieu E.E., Hodgen G.D. Noncompetitive antiestrogenic effect of RU 486 in blocking the estrogen-stimulated luteinizing hormone surge and proliferative action of estradiol on endometrium in castrate monkeys. Fertil. Steril. 52:1989;1055-1060.
27. Neulen J., Williams R.F., Breckwouldt M., Chwalisz K., Baulieu E.E., Hodgen G.D. Noncompetitive anti-estrogenic actions of progesterone antagonists in primate endometrium: enhancement of oestrogen and progesterone receptors with blockade of post-receptor proliferative mechanisms. Hum. Reprod. 11:1996;1533-1537.
28. Follesa P., Concas A., Porcu P., Sanna E., Serra M., Mostallino M.C., Purdy R.H., Biggio G. Role of allopregnanolone in regulation of GABA(A) receptor plasticity during long-term exposure to and withdrawal from progesterone. Brain Res. Rev. 37:2001;81-90.
29. Burch D.J., Spowart K.J.M., Jesinger D.K., Randall S., Smith S.K. A dose-ranging study of the use of cyclical hydroprogesterone with continuous 17β oestradiol. Br. J. Obstet. Gynaecol. 102:1995;243-248.
30. Noyes R., Hertig A.T., Rock J. Dating the endometrial biopsy. Fertil. Steril. 1:1950;3-25.
31. Clisham P.R., Cedars M.I., Geendale G., Fu Y.S., Gambone J., Judd H.L. Long-term transdermal estradiol therapy: effects on endometrial histology and bleeding patterns. Obstet. Gynecol. 79:1992;196-201.
32. Wen D.X., Xu Y.F., Mais D.E., Goldman M.E., McDonnell D.P. The A and B isoforms of the human progesterone receptor operate through distinct signaling pathways within target cells. Mol. Cell. Biol. 14:1994;8356-8364.
33. McDonnell D.P. Unraveling the human progesterone receptor signal transduction pathways (insights into antiprogestin action). Trends Endocrinol. Metab. 6:1995;133-138.